Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLOZIDPD
2024-514530-21-00Phase 4Authorised
- Sponsor
- CHU Amiens-Picardie
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of clozapine in Parkinson's disease (PD), sponsored by CHU Amiens-Picardie. Primary endpoint: Change in serum IgG levels from baseline to 6 months after clozapine initiation. Planned start Aug 2024; status: authorised.
02
Drugs
clozapine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2024-514530-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514530-21-00.